Sector Expert: Dr. KSS
Dr. KSS is the founder and editor-in-chief of BioPub.co. He is an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, he has been investing in biotech companies with great success. Dr. KSS earned his degrees at a top 10 U.S. institution, where he was an NIH scholar and graduated with top honors. He has extensive post-doctoral research experience and am board certified in internal medicine and also gastroenterology. His goal is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities.
Companies Commented On
- Acurx Pharmaceuticals LLC
Is there anything intracellular sigma peptide, the company's lead agent, can't do, asks Dr. KSS, MD, PhD, editor-in-chief of BioPub.co.
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile.
Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years.